A Phase 3 interventional study of NT 201 and Placebo in Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury, sponsored by Merz Pharmaceuticals GmbH. Active, not recruiting at 71 sites in 15 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 908 studies in Brain Injuries, Traumatic with a site in United States — 211 open to participants now, 249 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.
Among the 908 studies in Brain Injuries, Traumatic with a site in United States, this one is the 18th largest by enrollment of the 649 interventional ones that give a count, is one of 53 that started in 2019, is one of 26 in phase 3, reaches primary completion later than 24 of the 248 other live ones, and was the 544th registered.
1,722 studies on the registry are indexed under Brain Injuries, Traumatic; 448 are open to participants now.
Browse Brain Injuries, Traumatic studies →211 of the 908 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:
Andrew Mayer · Sites in United States
Ages 18–82 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–55
Columbia University · Sites in United States
Ages 18+
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Michigan · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Brain Injuries, Traumatic studies recruiting now, 122 (43%) set no upper age limit and 120 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
908 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 110 · Phase 3 39 · Phase 4 28
First in 1996; this study’s year is marked. 53 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 603 is above the median of 52 across 1,089 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 50 across the 649 interventional studies, 120 across the 257 observational. Of the 553 that completed or were terminated, 182 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 908 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz Pharmaceuticals GmbH, one of the names counted as Merz Pharma. Under that name alone:
Merz Pharmaceuticals GmbH is the lead sponsor of 61 studies on the registry; none are open to participants now.
Merz Pharma has 3 studies filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
83 of the studies in Brain Injuries, Traumatic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT06103201University of Maryland, BaltimoreHyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury | 2026-11-26 |
| NCT07733284Kessler FoundationHome-Based Walking for Thinking Skills in Persons With TBI | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT05702138Craig HospitalHigh Intensity Step Training After Traumatic Brain Injury | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 908 studies in Brain Injuries, Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
The following 4 to 5 treatment cycles will investigate the safety and tolerability of treatment with NT 201 (botulinum toxin) when administered in doses between 400 and 800 Units (Open Label Extension Period). All participants will receive the treatment and the dose will depend on whether only lower limb spasticity or combined upper and lower limb spasticity are treated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb. Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated.
Drug: NT 201
Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb. Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated.
Drug: NT 201 · Drug: Placebo
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Also known as: IncobotulinumtoxinA, Incobotulinumtoxin A, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at weeks 4 to 6
The MAS is a 6-grade scale
Time frame: Baseline to week 4-6
Co-Primary: Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6
The GICS s a 9-grade scale
Time frame: Week 4-6
Occurrence of treatment emergent adverse events [TEAEs] in the Main Period
Time frame: Baseline to week 12
Change from Study Baseline in Goal Attainment Scale [GAS] at Week 6
The GAS is a 6-grade scale
Time frame: Baseline to week 6
Global Impression of Change Scale (GICS) assessed by the study subject at Week 4 to 6
The GICS s a 9-grade scale
Time frame: Week 4-6
Global Impression of Change Scale (GICS) assessed by the caregiver at Week 4 to 6
The GICS s a 9-grade scale
Time frame: Week 4-6
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Jun 2025, 69 months.
Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's 69 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: incobotulinumtoxinA